New drug combo shows promise for Tough-to-Treat stomach cancer
NCT ID NCT03686488
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help patients live longer. The study is complete, and results suggest this approach may offer a new option for patients with few alternatives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAS 102 (Lonsurf) and ramucirumab (Cyramza)
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced stomach cancer who have run out of standard therapies, potentially extending survival.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to all patients. The combination may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States